Molecular genetics diagnostic company Mainz Biomed has entered a commercial partnership with TESTDNA for its ColoAlert test in Poland.
Mainz Biomed offers ColoAlert as an at-home detection test for colorectal cancer (CRC) and both companies will work together in the coming weeks to plan and roll out co-marketing activities to fully commercialise the test in the Polish market.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Mainz Biomed chief commercial officer Darin Leigh said: “Entering the Polish market is an important milestone for the company and we are thrilled by the opportunity to partner with TESTDNA to establish ColoAlert’s commercial footprint in this territory.
“TESTDNA is an exciting addition to our growing network of international laboratory partners who are committed to providing cutting-edge diagnostic screening tools to improve patient survival and disease prevention from deadly indications such as CRC, the second most lethal cancer in Europe.”
ColoAlert is a non-invasive test that is expected to facilitate better early identification of CRC than faecal occult blood tests.
The test leverages polymerase chain reaction technology to identify more cases of colorectal cancer than other stool tests.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThis test is commercially marketed in select EU countries via corporate health programmes, direct sales and independent laboratories.
Furthermore, the test will be assessed in the company’s US pivotal study, called ReconAAsense.
